Second Opinions for Pediatric Epilepsy Care

Why Visit Our Pediatric Epilepsy Center

We believe all children with refractory epilepsy should get a second opinion from at an accredited epilepsy center. If you bring your child to the University of Chicago Medicine Comer Children's Hospital, we work with your referring neurologist and your child’s pediatrician to review diagnosis and treatment. We also offer tests and treatments that may not be available at your community hospital.

Meet our Pediatric Epilepsy Physician Team

Some of the questions we address:

• Have your child's medications been given adequate time to work?
• Have the appropriate medications for your child’s seizure disorder been tried?
• Have other treatment options been explained or explored when, or in case, medications fail?

Comprehensive Re-evaluation

In addition to providing anticonvulsant (anti-seizure) medication for your child, we conduct a reassessment, looking for genetic causes of epilepsy and subtle brain abnormalities (cortical malformations) that can cause seizures. If we find your child has these abnormalities or genetic predispositions, there may be more effective treatment options available.

We also review your child's test results. We may recommend recording your child’s actual seizures to better understand his or her epilepsy. Once we’ve completed diagnostic testing (EEGs, neuroimaging and, possibly, genetic testing), we provide treatment options based on the results.

Maximize Your Child's Treatment Options

Because we are a Level 4 Epilepsy Center for children, the treatment options we offer are often more extensive than what is available at other hospitals. Some of the treatment options available at our Pediatric Epilepsy Center are:

• Targeted, minimally invasive surgical techniques performed with sophisticated technology
• Responsive neurostimulation (RNS)
• Vagus nerve stimulation (VNS)
• Ketogenic diets

To provide additional options to our patients, we often participate in pediatric epilepsy clinical trials, testing new drugs that are not yet widely available.